419 results about "Resistant cell" patented technology

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

The invention discloses glycosylated boron dipyrromethene fluorophore derivatives as well as a preparation method and application of the glycosylated boron dipyrromethene fluorophore derivatives. The method comprises the following steps: by taking glucose and glucosides thereof as action targets, connecting covalent bonds of the action targets to boron dipyrromethene fluorophore derivatives for photodynamics therapy, so that a third generation photosensitizer against cancer which can be used for targeted therapy is obtained. The dipyrromethene fluorophore derivatives containing glucose and glucosides are taken as study researches, activity study of in-vitro breast cancer-resistant cells MBA-MD-231 is expanded, a prodrug suitable for molecular targeted therapy is screened, and a foundation is laid for applying the glycosylated boron dipyrromethene fluorophore derivatives to targeted therapy of cancers. Moreover, the compound synthesis method is simple, readily available in raw materials, low in cost, few in side reactions, high in yield and simple in purification, and industrial production is promoted.

The invention discloses blank mixed micelle, and a preparation method and applications thereof. The blank mixed micelle comprises an amphiphilic copolymer and ginsenoside represented by formula I, ishigh in efficiency, is safe, is stable, is high in targeting performance, is excellent in homogeneity, is stable in quality, is convention in preparation technology, can be used for coating one or a plurality of active substances in drugs or cosmetics and health care substances, and is capable of forming mixed micelle containing loaded active substances. Compared with conventional nanometer micelle, the blank mixed micelle possesses following advantages: the mixed micelle loaded with active substances is excellent in drug forming performance, multiple drug resistance, stability, homogeneity, and safety performance, and is small in particle size; and the curative effect of loaded active drugs on drug resistant cells is better.

Methods of treating an individual who has been identified as having glycolysis dependent cancer are disclosed. The methods comprise the step of: administering to such an individual a combination of an anti-cancer composition that renders the cancer incapable of glycolysis and an autophagy inhibitor. Pharmaceutical compositions and kits comprising that renders the cancer incapable of glycolysis and an autophagy inhibit are also disclosed. Methods of treating an individual who has a disease characterized b cell degeneration and cell death due to autophagy are disclosed. The methods comprise administering to the individual a permeable form of a metabolic substrate that can be oxidized in the tricarboxylic acid cycle to produce NADH. Methods for identifying an autophagy inhibitor comprising performing a test assay using an apopto sis-resistant cell are disclosed.

The invention discloses a mytilus edulis enzymolysis polypeptide. The mytilus edulis enzymolysis polypeptide is characterized by containing the following amino acid sequence: Asp Leu Tyr. The mytilus edulis enzymolysis polypeptide is prepared by adopting the following steps of: (1) preparing homogenate from mytilus edulis meat, adding alkaline protease, deactivating the protease, centrifuging, and taking clear solution of the upper layer; (2) performing ultra-filtration on the clear solution, collecting hydrolysate with the molecular weight of below 3K, concentrating, and performing freeze drying; (3) performing chromatographic separation by adopting a DEAE-SepharoseFF ion exchange column; (4) performing chromatographic separation by adopting a Sephadex G-25 gel column; and (5) performing high performance liquid chromatography purification. The invention also discloses application of the mytilus edulis enzymolysis polypeptide prepared by the steps in prostatic cancer resistance. Compared with the prior art, the invention has the advantages that: the mytilus edulis is subjected to enzymolysis and purification by adopting an optimal protease and an optimal technology, a strong cell proliferation inhibiting effect is achieved when the obtained target peptide is applied to prostatic cancer resistant cells, and a feasible research path is provided for resisting prostatic cancer.

The invention discloses an anti-cancer medicinal aspirin platinum complex and a preparation method thereof. The method comprises the following steps of coordinating amine or heterocyclic amine on a platinum atom through a coordinated N atom and the coordination function of the platinum, introducing halogen or hydroxyl, carboxylate radical or substituted carboxylate radical through the coordination function, and oxidizing the platinum atom into tetravalent platinum, connecting aspirin molecular axially to form tetravalent platinum complex with one aspirin molecular single substitute or two aspirin molecular double substitutes axially. As the tetravalent state of the platinum is relatively inert, the toxic side effect on organs is small, and moreover, the uptake route of drug is changed, the anticancer activity of the drug is improved, the anti-tumor activity which is same to or even more excellent than that of cis-platinum is realized, and the killing function to the drug resistant cells is good. The preparation method provided by the invention is simple in structure, low in cost and suitable for industrial production.

The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.

The present invention relates to compositions and methods for reducing cell proliferation and / or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies.

The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.

The invention provides a breast cancer multidrug-resistant cell strain constructed by virtue of epirubicin induction, wherein the breast cancer multidrug-resistant cell strain has a collection number of CCTCC C201439. The invention further provides a method for constructing the breast cancer multidrug-resistant cell strain. According to the invention, an MDA-MB-231 / EPI drug-resistant strain is successfully established, wherein a drug-resistant index is 26.27 times, and obvious cross resistance is produced for taxol, etoposide and cis-platinum. A drug-resistant tumor cell model is provided for the following related researches so as to research drug-resistant tumor cell morphology and biological characteristics, research a tumor multidrug resistance mechanism, analyze sensitivity to chemotherapeutic drugs as well as screen chemotherapeutic drugs, develop tumor drug resistant reverse drugs and research and develop a more effective tumor therapeutic method, and the like.

The invention relates to a multidrug resistant cell strain for oophoroma, which is characterized in that a human oophoroma SKOV3 cell strain is selected as a parental cell; the action concentration of chemotherapeutics of etoposide (VP16) is gradually increased from 0.1 mu g / ml to 3 mu g / ml; and drug resistant SKOV3 / VP16 cell strain is established. The SKOV3 / VP16 cell can stably grow, transfer and reanimate in 3 mu g / ml VP16, makes the VP16 generate drug resistant index (RI) of 21.548, and performs intersect drug on MTX, DOX, DDP, VCR, 5-Fu and MMC except the VP16. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.

The invention belongs to the field of oncobiology and relates to a method of establishing a tumor multi-drug resistant cell mode in vitro. The method comprises the step of continuously culturing a sensitive tumor cell by taking ROS as an incubation drug to enable the sensitive tumor cell to generate multi-drug resistance. Moreover, the invention further relates to a human breast cancer multi-drug resistant cell strain established by virtue of the method. The cell strain is named MCF-7 / ROS and preserved in CCTCC (China Center for Type Culture Collection), wherein the address is 430072, Wuhan University, Wuhan, China; the preservation date is 28th, January, 2015; the preservation number is CCTCC-C201520. The method provided by the invention is simple in process and stable in modeling condition, the modeling cost can be remarkably lowered, and the method has wide applicability. The MCF-7 / ROS cell strain established by the method can serve as an advantageous experimental mode for researching related mechanism, target spot exploration and screening of new drugs.

The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof: [where R1 represents hydrogen atom or lower alkoxy group; R2 represents hydrogen atom, lower alkoxy group, optionally substituted phenyl group, (where R3 represents acyl group); X represents —CO— or —CH2—; and n-represents 1 or 2], as drugs for overcoming a resistance to anticancer drugs or drugs for enhancing an effect of anticancer drugs. The compounds represented by the general formula [1] have not only a function of overcoming the resistance to various anticancer drugs but also a function of enhancing the effect of various anticancer drugs to anticancer-drug sensitive cells. Thus, these compounds have excellent effects on resistant cells and also on sensitive cells, and in particular effective in the treatment of a cancer having an acquired resistance to an anticancer drug.

The invention relates to an environmental response type anti-tumor nanometer medicine with high medicine loading capacity, a carrier and a preparation method thereof. The nanometer medicine comprisesan amphiphilic polymer carrier and a medicine prodrug; the amphiphilic polymer carrier comprises a hydrophilic segment and a hydrophobic segment which are connected mutually; the hydrophilic segment comprises polyethylene glycol or poly(N-(2-hydroxypropyl)methacrylamide); the hydrophobic segment comprises D-alpha-tocopherol succinate; the medicine prodrug comprises a medicine for treating tumor aswell as a hydrophobic chain segment which is connected with the medicine through a chemical bond; and the hydrophobic chain segment comprises D-alpha-tocopherol succinate. The nanometer medicine hasthe characteristics of high medicine loading capacity, environmental responsiveness and adjustable and controllable grain size, and can achieve the properties that the tumor penetration ability is high, the tumor cell multidrug resistance is achieved, drug-resistant cells are killed in advance, tumor related fibroblast is not killed and tumor stem cells can be killed effectively according to composition of different polymers and the loaded prodrug molecule types.

The invention relates to the technical field of biomedicine, and in particular to a renal cancer sunitinib drug-resistant cell system and an establishing method and application of the renal cancer sunitinib drug-resistant cell system. 786-O cells and ACHN cells of a human renal clear cell carcinoma system are adopted as objects for establishing a subcutaneous tumor-bearing nude mouse model; the clinical conventional dose of the sunitinib is used for treating a tumor-bearing nude mouse; and through multiple times of in-vivo continuous passage and drug pressure screening, the renal cancer drug-resistant cell system free of restraints of the sunitinib in vitro and vivo is finally obtained through separate culture and named as 7SuR and ACSuR. The established renal cancer sunitinib drug-resistant cell system can better simulate clinical drug resistance and provides an important platform for studying renal cancer targeted drug resistance mechanism, reversing renal cancer cell drug resistance and developing and evaluating new anti-cancer drugs.

The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.

The invention discloses a mixed photonic crystal, and a preparation method and applications thereof. The mixed photonic crystal comprises a polyethylene glycol 200 diacrylate inverse opal skeleton andmetacrylic acid ester gelatin and magnetic nanoparticles used for filling apertures of the skeleton. According to the preparation method, silica colloidal microspheres are taken as a template, a pre-gel A is added for reaction and polymerization, and the silica colloidal microspheres are removed so as to obtain the polyethylene glycol 200 diacrylate inverse opal skeleton; pre-gel B is added intothe polyethylene glycol 200 diacrylate inverse opal skeleton for reaction and polymerization so as to obtain a finished product. The mixed photonic crystal can be used in drug resistance cell detection as a carrier. The mixed photonic crystal is high in stability, possesses excellent biocompatibility and magnetic responsiveness; the preparation method is simple; the operationality is high; the preparation method is friendly to the environment; the mixed photonic crystal can be used in drug resistant cell detection; the surface of the mixed photonic crystal can be loaded with folic acid; and simple and effective capturing of myeloid leukemia drug resistance cells can be realized with high specificity and sensitivity.

The invention relates to the field of drug-resistance cell systems, and particularly relates to a drug-resistance cell system and a preparation method thereof. The method comprises the following steps: inoculating the lung cancer cells to a culture medium containing a 21-93nM lung cancer targeted drug; culturing until cells can normally live and multiply under the same concentration; improving andculturing at 50nM concentration difference; improving and culturing at concentration difference of every 100nM when the cell multiplying inhibiting concentration is 4 times of IC50; improving and culturing at concentration difference of every 1 microns when the drug sieving concentration is 8 times of IC50; and obtaining the drug-resistance cell systems for the lung cancer when the lung cancer cells can live and multiply in a cell culture system of 10 microns osimertinib. According to the method, the drug-resistance cell system is prepared on the basis of gradually increasing the concentration of drugs in the culture medium; the foundation is provided for later simulation of clinical drug resistance, researching of drug resistance mechanism of lung cancer targeted drugs, and developing ofeffective drug resisting drugs.

A sorafenib antitumor platinum (II) complex targeted at human lung cancer drug-resistant cells is disclosed. The chemical structure of the complex is shown as follows in the description. The complex shows excellent antitumor activity in vitro, has potential medicine value and can be used for preparing various antitumor medicines.

The invention discloses an application of d-borneol serving as an antitumor drug sensitizer. According to the application of d-borneol serving as the antitumor drug sensitizer, d-borneol serving as the antitumor drug sensitizer is used for assisting in antitumor drugs. The inventor discovers that after the concentration of d-borneol which has no remarkable growth influence on cells is increased, the sensitivity of non-resistant cells to antitumor chemical drugs is greatly improved, that is, the concentration of the antitumor chemical drugs for killing tumor cells can be reduced on the basis of addition of d-borneol, the curative effect is not reduced, toxic and side effects of the chemical drugs are reduced along with reduction of the concentration of the chemical drugs, and normal cells of people are protected. D-borneol has low toxicity for normal cells of people and does not have remarkable influence basically, and accordingly, d-borneol is a potential high-efficient low-toxicity chemical drug sensitizer.

The invention provides a 2-aminoimidazopyridine derivative shown as a formula I, a formula II, a formula III or a formula IV and further provides a preparation method and application of the 2-aminoimidazopyridine derivative. An experiment shows that the 2-aminoimidazopyridine derivative has a remarkable proliferation inhibition effect on tumor cells (including an over-expressed wild type EGFR (Epidermal Growth Factor Receptor) human epidermal carcinoma cell line A431 and a Gefitinib drug-resisting human lung adenocarcinoma cell line H1975) related to the activity of EGFR tyrosine kinase in the aspect of a cell level, especially has a relatively good inhibition effect on the drug-resisting cell line H1975, has relatively weak inhibition activity on a low-expression EGFR human colon cancer cell line SW620 and can be applied to preparation of corresponding anti-tumor cell medicines. A general formula is shown in the description.

The invention provides an ex-vivo test kit for testing the effectiveness of reversers of multidrug resistance in the blood, serum or plasma of a patient containing the reversers, the kit comprising, a plurality of cell membranes from highly drug-resistant cells, the cell membranes containing proteins which pump drugs and the membranes being respectively attached to a plurality of support surfaces, and a dye which provides a light signal, which dye is pumped by the proteins contained in the membranes.

The invention discloses albumin nanoparticles realizing co-delivery of an antitumor drug and an MRI (magnetic resonance imaging) contrast medium and a preparation method of the albumin nanoparticles and further provides an albumin nanoparticle vector containing the MRI contrast medium, and drug loading is realized through electrostatic adsorption and coordination between the drug and the vector as well as crosslinking of amino acid residues of the vector. The invention further discloses an optimal preparation technology of the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium and a function of the albumin nanoparticles in diagnosis and treatment combination of tumors. According to the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium, the drug uptake ratio of cells can be increased, and drug efflux caused by drug-resistant cells is reduced, so that drug resistance is reversed, and efficient delivery of the drug is realized; the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium have excellent T1 weighted imaging capability and an effective means is provided for the diagnosis and treatment combination of the tumors.

The invention discloses a targeted protein degradation c-Met degradation agent as well as a preparation method and application thereof. The invention provides a c-Met degradation agent based on a targeted protein degradation PROTAC strategy, a preparation method thereof and application of the c-Met degradation agent in the treatment of non-small cell lung cancer, gastric cancer and other cancers.The compound has a remarkable c-Met degradation effect and a remarkable cell proliferation inhibition effect, has the potential of serving as an anti-tumor drug to treat tumors, shows remarkable proliferation inhibition activity in an EBC1 drug-resistant cell strain constructed by lentiviral transfection, is obviously superior to a small molecule inhibitor LXM262. and obviously improves the cell selectivity. The compound has significant advantages in overcoming tumor c-Met acquired drug resistance, especially the compound S27 only provides good activity for c-Met dependent EBC-1 lung cancer cells, it is indicated that the compound S27 has good cell selectivity while the original small molecule inhibitor is multi-target, and the compound also has an inhibition effect on a c-Met non-dependent cell line.

The invention discloses a self-cloning new human tumor drug-resistant related gene, namely TCRP1, wherein the gene and drug resistance generation of tumor chemotherapy platinum drugs has confidential relation. The expression of TCRP1 in platinum secondary drug-resistant tumor cell strains such as Tca8113 / PYM, A549 / DDP, Coc1 / DDP is raised, and the expression of TCRP1 in primary platinum drug-resistant cell strain such as lung cancer 95D is obviously superior to that of other sensitive cell strains of lung cancer. The gene is located in human chromosome 11q13.4, wherein the total length of sequence is 1834bp, the open reading frame is 708bp, and 235 amino acids are encoded. The application not only provides new information for tumor drug-resistant mechanism, but also provides new target for the design of anti-tumor drug-resistant drugs.

The invention discloses a method for screening nasopharyngeal carcinoma radiotherapy resistant cells by using a radioactive irradiation mode. The method adopts a screening mode of radioactive gradient increasing. By adopting the method, cells can adapt to high-dose radioactive irradiation more rapidly within a relatively short time, the time of growth recovery after single high-dose radioactive irradiation can be shortened, the possibility of generating radiotherapy resistance can be increased, and meanwhile, the investment of manpower, material resources and time can be reduced. The constructed nasopharyngeal carcinoma radiotherapy resistant cells are used for providing a good cell model for the study on nasopharyngeal carcinoma radiotherapy resistance. The method disclosed by the invention is suitable for nasopharyngeal carcinoma cell strains cultured in vitro, and also can be used for providing references for the establishment of other tumor radiotherapy resistant cells.

The invention discloses a lotion for treating hormonous dermatitis. Besides multiple moisturizing effective ingredients, a pseudoalteromonas leavening extract is added to serve as a core of the lotion, is exopolysaccharide extracted from pseudoalteromonas, and can be used for promoting synthesis of I-type, III-type and IV-type collagen, so that the collagen has better quality; the capability of repairing a wound surface can be improved by means of the function of activating immune cells, and the defense capability of the skin system can be improved; because the skin barrier of hormonous dermatitis is destroyed, the collagen binding capability is reduced, the skin barrier is reconstructed by activating resistant cells of the skin, the metabolic cycle is improved, and the skin can quickly metabolize dermatitis to achieve a curing effect. The lotion is reasonable in formula, natural in ingredients, remarkable in curative effect and extremely low in recurrence rate, and can be used for effectively treating flushed face, acne rosacea, serious acne, inflammatory edema, acute pustular eruption and other symptoms caused by hormonous dermatitis, and the hormonous dermatitis can be finally cured.

The invention relates to a mouse anti-human CIAPIN1 monoclonal antibody for confirming multi-drug resistant gastric cancer, and a preparation method thereof. The invention is characterized in that the monoclonal antibody is obtained by adopting the hybrid tumor technology; the heavy chain is 1gG1; the light chain is k; the molecular weight is 39KD; and the affinity is 3.6x10. The preparation method comprises the following steps of: (1) synthesizing primers; (2) synthesizing single-chain DNA by carrying out reverse transcription on SGC-7901 / VCR general RNA of a human gastric-cancer multi-drug resistant cell; (3) expanding human CIAPIN1 gene cDNA by using the primers F and R and by adopting a PCR method; (4) constructing CIAPIN1 gene induction expression plasmids pET28-CIAPIN1 and pGEX-CIAPIN1; (5) constructing engineering bacteria B21-CIAPIN1 and DE3-CIAPIN1; (6) using the engineering bacteria B21-CIAPIN1 and DE3-CIAPIN1 to carry out prokaryotic expression and purification on CIAPIN1 protein; (7) using CIAPIN1 protein to immunize a 4-week-old Balb / C mouse so that mouse anti-human CIAPIN1 antibody is generated; and (8) using the serum of the immunized mouse to prepare the mouse anti-human CIAPIN1 monoclonal antibody. The invention can better identify multi-drug resistant gastric cancer and non-multi-drug resistant gastric cancer of clinical gastric cancer patients, and predict clinical prognosis of the gastric cancer patients.